MetaTech AP Reveals 2027 Strategy, Partners with Zheng Yang Biomedical

On October 15, 2026, MetaTech AP Inc. announced its 2027 growth strategy, highlighting key partnerships and market forecasts. The company's revenue for the first nine months of 2026 reached NT$1.391 billion, marking a 21% increase from the previous year. This growth is driven by expansion in electronics and biomedicine sectors.

MetaTech AP reported a 24.7% increase in its electronics business, focusing on AI servers, power supplies, and semiconductors. Meanwhile, the company's venture into regenerative medicine, initiated in 2013, has yielded advancements in cell therapy technologies.

The new partnership with Zheng Yang Biomedical aims to build a regenerative medicine supply chain. MetaTech AP will manufacture human platelet lysate, while Zheng Yang will handle global sales. They are also collaborating on Elate Ocular®, targeting the dry eye disease market projected to grow significantly by 2028.